Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ADRISK
- 05 Sep 2018 Planned End Date changed from 1 Apr 2022 to 1 Aug 2022.
- 05 Sep 2018 Planned primary completion date changed from 1 Apr 2022 to 1 Aug 2022.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.